Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90048


To determine the re-operation rate (band revision, band replacement and explants resulting from serious adverse device-related event {SADE}) of gastric banding at 4 and 5 year post implant.


Inclusion Criteria: - Subjects eligible to participate in this study must fulfill all of the following criteria: 1. Able to comprehend, follow and give informed consent; 2. 18 to 60 years of age (inclusive); 3. Body Mass Index (BMI) of > 40 kg/m2 and £ 55 kg/m2, or BMI ³ 35 kg/m2 and < 40 kg/m2 with one or more co-morbid conditions. 4. Candidate for surgical weight loss intervention in accordance with the Instructions For Use (i.e., meets acceptable health criteria for major surgery). Exclusion Criteria: 1. Women who are currently pregnant. 2. Previous malabsorptive or restrictive procedures performed for the treatment of morbid obesity. 3. Documented history of drug and/or alcohol abuse within 2 years of the Screening Visit (1a). 4. Presence of any of the following medical conditions; 1. Inflammatory diseases of the gastrointestinal tract, including severe intractable esophagitis, gastric ulceration or duodenal ulceration, or specific inflammation such as Crohn's disease; 2. Severe cardiopulmonary disease or other serious organic disease; 3. Upper gastrointestinal bleeding conditions such as esophageal or gastric varices or intestinal telangiectases; 4. Portal hypertension; 5. Anomalies of the gastrointestinal tract such as atresia or stenosis; 6. Cirrhosis of the liver; 7. Chronic pancreatitis; 8. Patients on chronic, long-term steroid treatment or steroids within 15 days of surgery; 9. Unable or unwilling to comply with dietary restrictions required by this procedure; 10. Known allergy to materials contained within the band or its injection port (silicone elastomer containing 10% BaSO4, polyetheretherketone (PEEK), and cobalt chromium) 5. Presence of terminal illness with life expectancy of £ 5 years. 6. Inability to refrain from use of anticoagulants or aspirin within 15 days prior to surgery. 7. Acute or chronic infection (localized or systemic). 8. Participation in another clinical trial within 8 weeks of the Screening Visit (1a) and for the duration of this trial. 9. Any medical condition or finding for which the Investigator utilizes their medical discretion to determine the subject should be excluded due to inability to understand or follow study procedures.



Primary Contact:


Backup Contact:


Location Contact:

Los Angeles, California 90048
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.